Fiona Girdler
Dr Ian Brotherick
Professor Thomas Lennard
Dr James Young
Dr Brian Shenton
et al. | Changes in the expression of oestrogen receptors (ER alpha and ER beta) in the MCF7 cell line with endocrine treatments | 2002 |
|
Fiona Girdler
Dr Ian Brotherick
William Cunliffe
Professor Thomas Lennard
Dr Brian Shenton
et al. | ER alpha and ER alpha exon5 expression in tamoxifen treated tumours | 2002 |
|
Dr Ian Brotherick
Susan Stamp
William Cunliffe
Dr Gail Higginbottom
Dr James Young
et al. | Neoadjuvant tamoxifen treatment and its effect on MUC1 expression in primary breast cancer | 2002 |
|
Dr Ian Brotherick
Susan Stamp
Fiona Girdler
William Cunliffe
Professor Thomas Lennard
et al. | The influence of tamoxifen treatment on E-cadherin expression in primary breast cancer | 2002 |
|
Fiona Girdler
Dr Ian Brotherick
William Cunliffe
Professor Thomas Lennard
Dr James Young
et al. | Three weeks of tamoxifen treatment alters the expression of ER alpha, ER beta and pS2 | 2002 |
|
Fiona Girdler
Dr Ian Brotherick
Dr Brian Shenton
| ARMS (TM) allele-specific amplification-based detection of mutant p53 DNA and mRNA in tumors of the breast | 2001 |
|
Fiona Girdler
Dr Ian Brotherick
Professor Thomas Lennard
Dr James Young
Dr Brian Shenton
et al. | Changes in the expression of oestrogen receptors (ER alpha and ER beta) in the MCF7 cell line with endocrine treatments. | 2001 |
|
Dr Ian Brotherick
Fiona Girdler
Dr Brian Shenton
| The variation in expression of cytokeratin phenotypes in primary breast cancer | 2001 |
|
Fiona Girdler
Dr Ian Brotherick
William Cunliffe
Professor Thomas Lennard
Dr James Young
et al. | Three weeks of tamoxifen treatment alters the expression of ER alpha, ER beta and pS2. | 2001 |
|
Fiona Girdler
Dr Brian Shenton
Dr James Young
Dr Ian Brotherick
| Use of the monoclonal antibody DAKO-ERβ (8D5-1) to measure oestrogen receptor beta in breast cancer cells | 2001 |
|
Fiona Girdler
Dr Ian Brotherick
| The oestrogen receptors (ERα and ERβ) and their role in breast cancer: A review | 2000 |
|
